Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.53 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22269020 | 0.82 | HCAR3 (0.59) | P4HTMP4HA1MIFMAOBKDM4E | |
| SCHEMBL841772 | 0.82 | KCNH2 (0.57) | P4HTMP4HA1MIFMAOBKDM4E | |
| SCHEMBL841296 | 0.80 | TSHR (0.59) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL2428778 | 0.79 | HCAR3 (0.63) | P4HTMP4HA1MIFMAOBKDM4E | |
| SCHEMBL7269223 | 0.79 | MAPK1 (0.56) | NPC1ALDH1A1RAB9A | |
| SCHEMBL841762 | 0.78 | GRM5 (0.54) | P4HTMP4HA1MIFNPC1RAB9A | |
| SCHEMBL840824 | 0.78 | P4HTM (0.51) | P4HTMP4HA1MIFMAOBKDM4E | |
| SCHEMBL9180148 | 0.76 | P4HTM (0.66) | P4HTMP4HA1MIFKDM4ENPC1 | |
| SCHEMBL4483140 | 0.75 | P4HTM (0.47) | P4HTMP4HA1MIFMAOBKDM4E | |
| SCHEMBL1019074 | 0.75 | L3MBTL1 (0.65) | P4HTMP4HA1MIFKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110117069-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | IMTM GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117069-A1 | METHOD FOR ACTIVATING REGULATORY T-CELLS | ANPEP, DNPEP, RNPEP | P4HTM 1057/4885P4HA1 1092/4885MIF 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.